Overall, these findings indicate potential utility of second generation mTOR inhibitor/ruxolitinib combinations in CRLF2-re/JAK2-mutated Ph-like ALL, but additional in vivo studies using prolonged regimens of drug administration are needed to support this premise. Here, JAK2 is linked to acute lymphoblastic leukemia.